4:48 PM
 | 
Sep 05, 2013
 |  BC Extra  |  Company News

FDA to again review Endo's Aveed

FDA accepted for review a resubmitted NDA from Endo Health Solutions Inc. (NASDAQ:ENDP) for Aveed testosterone to treat male hypogonadism. The PDUFA date...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >